Scalp psoriasis: report of efficient treatment with secukinumab

Pistone, Giuseppe; Tilotta, Giovanna; Gurreri, Rosario; Curiale, Salvatrice; Bongiorno, Maria Rita

doi:10.1080/09546634.2018.1529380

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2018, two case series reported the real‐life experience of secukinumab in the everyday clinical practice. 43,44 Pistone et al reported a 10‐patients case series; all of them had a clinical improvement of scalp psoriasis, as 6/10 had a complete remission, whereas the remaining 4/10 reached a PSSI 90 44 . The case series by Platsidaki et al mentioned a single patient with scalp psoriasis with a −13 improvement of PSSI (baseline, PSSI = 20; week 16: PSSI = 7) 43…”

Section: Biologic Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review

Camela

Ocampo‐Garza

Cinelli

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Scalp psoriasis represents the most common difficult-to-treat area in psoriasis patients. Its presence is linked to severe discomfort and impairment of quality of life given the associated symptoms (most of all, scaling and pruritus) and the location in a highly visible area, thus a prompt treatment is required. Its management may be challenging as the scalp is quite sensitive to long-term treatment with topical corticosteroids and usually resistant to topical and systemic agents. Likely, the currently available therapeutic armamentarium has been enriched with biologicals and small molecules that revolutionized psoriasis treatment and that of scalp psoriasis. Nevertheless, the lack of international dedicated guidelines pushed us to perform a comprehensive review on the efficacy and safety of biologics and small molecules on scalp psoriasis with the aim to put the basis for a therapeutic algorithm. After reviewing all the available evidence on the short-term and long-term efficacy of biologics and small molecules on scalp psoriasis the use of the newest biologics (anti-IL-17 and anti-IL-23) seems to be linked to the highest clinical performances in controlling scalp psoriasis. However, head-to-head comparisons between different biologics or biologics and small molecules are lacking. Hence, treatment selection should always be individualized.

show abstract

Section: Biologic Treatmentmentioning

confidence: 99%

“…9 Current scientific literature regarding secukinumab includes also real-world studies. [42][43][44] The largest study population is represented by the 83 patients that Rompoti et al included in a single-center, realworld study. All patients received secukinumab at labeled dosage.…”

Section: Secukinumabmentioning

confidence: 99%